PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients

PD-1 Antibody for the Prevention of Adenomatous Polyps and Second Primary Tumors in Patients With Lynch Syndrome: An Open-label, Multicenter, Randomized Controlled Clinical Trial

This study aims to explore the role of PD-1 Antibody in preventing adenomatous polyps and second primary tumors in patients with Lynch Syndrome. There two arms, one is the experimental arm (PD-1 antibody prevention group) and the other is the control arm (routine follow-up group). For the experimental group, Tripleitriumab (PD-1 antibody) is given every 3 months for a year.

Study Overview

• Status: Recruiting
• Conditions: Lynch Syndrome
• Intervention / Treatment: Drug: PD-1 Antibody

Detailed Description

Lynch syndrome (LS) is a hereditary cancer syndrome that causes the majority of hereditary CRC and approximately 3% of all CRC. LS significantly increases the risk for an individual to develop CRC during their lifetime. Individuals with LS also have an increased risk to develop extracolonic cancers, including endometrial, gastric, ovarian, upper urinary tract, small bowel, biliary tract, CNS, and certain types of skin cancer. Given the hereditary nature of this syndrome, preventing second primary tumors in patients with Lynch Syndrome after surgery to the primary site is very important.

The purpose of this study is to prevent adenomatous polyps and second primary tumors using PD-1 antibody (Tripleitriumab) in patients with Lynch Syndrome.

The primary outcome of this study is the incidence of intestinal adenomatous polyps and secondary primary tumors. The secondary outcomes are the incidence of colorectal adenomatous polyps greater than 1cm, incidence of high-grade colorectal polyps, treatment-related adverse events, disease-free Survival and overall Survival.

There are two groups: the PD-1 antibody prevention group and the routine follow-up group. For the PD-1 antibody prevention group, participants will receive Toripalimab 240mg IV every 3 months for a year. For the routine follow-up group, there is no drug intervention.

This whole study will take 5 years: the first year for recruiting and the latter four years for follow-up.

• Study Type: Interventional
• Enrollment (Anticipated): 260
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Peirong Ding, MD, Ph D; Phone Number: 00862087343124; Email: dingpr@sysucc.org.cn
• Study Contact Backup: Name: Wu Jiang, MD, Ph D; Phone Number: 00862087343920; Email: jiangwu@sysucc.org.cn

Study Locations

• China
  • Guangdong
    • Guangzhou, Guangdong, China, 510060
      • Recruiting
      • Sun Yat-Sen University, Cancer Center
      • Contact: Peirong Ding, MD, Ph D; Phone Number: 00862087343124; Email: dingpr@sysucc.org.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Lynch syndrome with germline variants of MLH1, MSH2, or EPCAM (pathogenic or likely pathogenic variants)
2. Necessary treatments have been done, such as surgery, chemotherapy, radiation therapy, etc.
3. Have a resection, including right hemicolectomy, left hemicolectomy, sigmoid colectomy, or anterior resection of rectal cancer, or endoscopic adenoma resection
4. Aged 18-70 years old
5. Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 1
6. White blood cell (WBC) > 4000/mm3, Platelet count >100000/mm3, HB >10 g/dL
7. Serum glutamic-oxaloacetic transaminase (SGOT) < 1.5 × the upper limit of normal (ULN), Serum glutamic pyruvic transaminase (SGPT) < 1.5 × ULN prior to randomization, Total bilirubin (TBIL) < 1.5 mg/dL
8. Serum creatinine (Scr) <1.8 mg/dL

Exclusion Criteria:

1. Lynch syndrome with germline variants of MSH6 and PMS2
2. Previous immunotherapy has been taken, such as anti-PD-1, anti-PD-L1, etc.
3. Long-term use of aspirin
4. Suffering from autoimmune diseases
5. Active infection with hepatitis B or hepatitis C (high copy number of viral DNA) or human immunodeficiency virus (HIV)
6. Other clinically serious active infections (NCI-CTC 4.0)
7. With cachexia or organ dysfunction
8. Suffering from seizures requiring treatment (such as steroids or antiepileptic therapy)
9. Unable to participate or complete the study due to substance abuse, or medical, psychological, or social disorder
10. Known allergy to any drugs in this study
11. Pregnant or nursing women, or women of childbearing potential who are not using adequate contraception
12. Any unstable condition or situation that could compromise the safety and compliance of participants.
13. Failure to sign an informed consent form

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Prevention group; Toripalimab: 240mg IV every 3 months for a year	Drug: PD-1 Antibody; Toripalimab: 240mg IV every 3 months for a year; Other Names: Toripalimab
No Intervention: Follow-up group; Routine follow-up, no intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The percentage of patients from randomization to the first appearance of one of the following: adenomatous polyps or second primary tumors	up to 5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The percentage of patients developing polyps greater than 1cm within 5 years from randomization		up to 5 years
The percentage of patients developing high-grade polyps on pathology within 5 years from randomization.		up to 5 years
Treatment-related adverse events	Incidence and severity of adverse events as assessed by NCI CTCAE V4.0	up to 5 years
Effectiveness with different genotypes or phenotypes	Estimated the percentage of patients with different genotypes or phenotypes not developing polyps or second primary tumors within 5 years from randomization.	up to 5 years
Disease-free Survival	defined as the time from randomization to the first appearance of one of the following: primary tumor recurrence, or death without cancer event; or censored at date of last follow-up	up to 5 years
Overall Survival	defined as the time from randomization to death from any cause. Participants who were alive or lost to follow-up at the time of the analysis were censored at the date they were last known to be alive	up to 5 years

Collaborators and Investigators

• Sponsor: Sun Yat-sen University
• Collaborators: Guangdong Provincial Hospital of Traditional Chinese Medicine; Fujian Cancer Hospital; Second Affiliated Hospital, School of Medicine, Zhejiang University; Guangdong Provincial People's Hospital; The Third Affiliated Hospital of Kunming Medical College.
• Investigators: Study Chair: Peirong Ding, MD, Ph D, Sun Yat-sen University

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2020
• Primary Completion (Anticipated): December 31, 2023
• Study Completion (Anticipated): December 31, 2025

Study Registration Dates

• First Submitted: January 13, 2021
• First Submitted That Met QC Criteria: January 14, 2021
• First Posted (Actual): January 15, 2021

Study Record Updates

• Last Update Posted (Actual): January 20, 2021
• Last Update Submitted That Met QC Criteria: January 18, 2021
• Last Verified: January 1, 2021

More Information

Terms related to this study

• Keywords: Prevention; Toripalimab; Lynch Syndrome
• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Metabolic Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Neoplasms, Glandular and Epithelial; Disease; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Genetic Diseases, Inborn; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Colorectal Neoplasms; Neoplastic Syndromes, Hereditary; DNA Repair-Deficiency Disorders; Adenoma; Syndrome; Colorectal Neoplasms, Hereditary Nonpolyposis; Adenomatous Polyps; Physiological Effects of Drugs; Immunologic Factors; Antibodies
• Other Study ID Numbers: B2020-059-01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No